BA
ABEO icon

BlackRock Advisors’s Abeona Therapeutics ABEO Stock Holding History

BlackRock Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-112
Closed -$7K – 3750
2016
Q1 		$7K Hold
112
– – ﹤0.01% 3618
2015
Q4 		$9K Sell
112
-98
-47% -$9.83K ﹤0.01% 3637
2015
Q3 		$21K Buy
210
+5
+2% +$664 ﹤0.01% 3503
2015
Q2 		$26K Buy
+205
New +$30.8K ﹤0.01% 3438

Other funds holding ABEO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's ABEO Position: Q2 2016 in Review

BlackRock Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2016, closing a stake of 112 shares — an estimated $7K sold.

BlackRock Advisors first reported a position in ABEO in Q2 2015 and held it in 4 quarters. The position peaked at $26K in Q2 2015. 37 funds tracked by Wall St. Rank hold ABEO as of Q2 2016.

  • BlackRock Advisors reported no remaining Abeona Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Advisors sold 112 Abeona Therapeutics shares in Q2 2016, an estimated $7K.
  • BlackRock Advisors first reported a position in Abeona Therapeutics in Q2 2015 and held it in 4 quarters.
  • BlackRock Advisors's Abeona Therapeutics position peaked at $26K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2016.

Based on BlackRock Advisors's 13F filing for Q2 2016, filed 10 Aug 2016.